Naari

Naari AG is a Swiss pharmaceutical company established on December 17, 2007, that specializes in women's health, with a particular focus on hormones. The company's name, 'Naari', is derived from the Sanskrit word for woman and reflects its core mission. It was co-founded by Chairman Dr. Hermann Osterwald, a pharmaceutical industry expert with over 35 years of experience, and CEO Prithi S Kochhar, a third-generation pharmaceutical entrepreneur. Naari operates on a vertically integrated business model, controlling the development and manufacturing of fermentation intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Formulations (FDFs).

The company's operational headquarters and a state-of-the-art Research and Development facility are located in Noida, India, with manufacturing infrastructure situated in Kashipur, India. This structure supports Naari's "in market for market" business model, aiming to address unmet market needs with differentiated products. The business generates revenue through the sale of its extensive portfolio of generic APIs and FDFs, which are distributed in over 50 countries. Naari serves various aspects of female health across all age groups, from puberty to post-menopause. Its product lines include treatments for menstrual regulation, acne, endometriosis, and hormonal contraceptives, as well as supplements and medical management for pre- and post-pregnancy care.

Naari has pursued growth through strategic acquisitions. In October 2019, the company acquired three Abbreviated New Drug Applications (ANDAs) from OC Pharm in the U.S. This was followed by an acquisition of ten ANDAs from Intas Pharmaceuticals, a move that expanded its U.S. market access to an estimated USD 900 million. In December 2019, Naari secured a significant equity investment of $17.5 million from Ascent Capital. Through its associate company, Navad Life Sciences, Naari also maintains a robust pipeline of innovative products at various stages of development and clinical trials. Naari was acquired by Tenshi Life Sciences on May 1, 2017.

Keywords: women's health, pharmaceuticals, hormones, active pharmaceutical ingredients, finished dosage formulations, generic drugs, hormonal contraceptives, endometriosis treatment, menstrual regulation, Prithi S Kochhar, Dr. Hermann Osterwald, Naari AG, Navad Life Sciences, vertically integrated pharma, Ascent Capital, Tenshi Life Sciences, API manufacturing, FDF manufacturing, reproductive health, post-menopause health